Exact Mass: 628.3907912

Exact Mass Matches: 628.3907912

Found 292 metabolites which its exact mass value is equals to given mass value 628.3907912, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Lopinavir

N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide

C37H48N4O5 (628.3624517999999)


Lopinavir is only found in individuals that have used or taken this drug. It is an antiretroviral of the protease inhibitor class. It is marketed by Abbott as Kaletra, a co-formulation with a sub-therapeutic dose of ritonavir, as a component of combination therapy to treat HIV/AIDS.Lopinavir inhibits the HIV viral protease enzyme. This prevents cleavage of the gag-pol polyprotein and, therefore, improper viral assembly results. This subsequently results in non-infectious, immature viral particles. D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors CONFIDENCE standard compound; INTERNAL_ID 2288 Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

LysoPI(20:0/0:0)

[(2R)-2-hydroxy-3-(icosanoyloxy)propoxy]({[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy})phosphinic acid

C29H57O12P (628.3587451999999)


LysoPI(20:0/0:0) is a lysophosphatidylinositol. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic. However, it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Lysophosphatidylinositols can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. LysoPI(20:0/0:0), in particular, consists of one chain of arachidic acid at the C-1 position.

   

Cholylglycyltyrosine

3-(4-hydroxyphenyl)-2-[2-(4-{5,9,16-trihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)acetamido]propanoic acid

C35H52N2O8 (628.3723472)


   

Lysocellin

2-[6-[6-[5-[5-Ethyl-2-hydroxy-5-(1-hydroxypropyl)-3-methyloxolan-2-yl]-3,5-dimethyloxolan-2-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-3,5-dimethyloxan-2-yl]ethaneperoxoic acid

C34H60O10 (628.418626)


   

Plactin D

N-{3-[14-benzyl-8,11-bis(2-methylpropyl)-3,6,9,12,15-pentaoxo-5-(propan-2-yl)-1,4,7,10,13-pentaazacyclopentadecan-2-yl]propyl}guanidine

C32H52N8O5 (628.4060462)


   

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

[(2R)-3-(decanoyloxy)-2-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-(decanoyloxy)-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

[(2R)-2-(decanoyloxy)-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-3-(decanoyloxy)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-3-(decanoyloxy)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-3-(decanoyloxy)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-3-(decanoyloxy)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

[(2R)-2-(decanoyloxy)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C33H57O9P (628.3740002)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   
   
   
   
   
   

Agelaxanthin C

7,8-Didehydro-3,8,19-trihydroxymethoxy-3-methoxy-beta,kappa-caroten-6-one

C41H56O5 (628.4127526)


   

(2R,2R,3S,3S)-2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

(2R,2R,3S,3S)-2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

onchitriol II D|Onchitriol IID

onchitriol II D|Onchitriol IID

C36H52O9 (628.3611142)


   
   

3-O-(2,4-Di-O-methyl-beta-D-xylopyranoside)-Cholestane-3,4,6,8,15,24-hexol

3-O-(2,4-Di-O-methyl-beta-D-xylopyranoside)-Cholestane-3,4,6,8,15,24-hexol

C34H60O10 (628.418626)


   

(22S,25S)-1alpha,2beta,3alpha,5alpha-tetrahydroxy-furo-spirostane-26-yl O-beta-D-glucopyranoside|tupistroside C

(22S,25S)-1alpha,2beta,3alpha,5alpha-tetrahydroxy-furo-spirostane-26-yl O-beta-D-glucopyranoside|tupistroside C

C32H52O12 (628.3458592)


   

Me ester,Tri-Ac-(2alpha,3beta)-2,3,30-Trihydroxy-12-oleanen-28-oic acid

Me ester,Tri-Ac-(2alpha,3beta)-2,3,30-Trihydroxy-12-oleanen-28-oic acid

C37H56O8 (628.3974976000001)


   

3-(2,16,19,20-tetradehydro-17-oxocuran-10-yl)vobasan-17-oic acid methyl ester|vobatricine

3-(2,16,19,20-tetradehydro-17-oxocuran-10-yl)vobasan-17-oic acid methyl ester|vobatricine

C40H44N4O3 (628.3413234)


   

3-O-(2,3-dimethylbutanoyl)-13-O-dodecanoyl-20-deoxyingenol

3-O-(2,3-dimethylbutanoyl)-13-O-dodecanoyl-20-deoxyingenol

C38H60O7 (628.4338809999999)


   

milbemycins VM48641

milbemycins VM48641

C36H52O9 (628.3611142)


   
   

29-(alpha-L-arabinofuranosyloxy)-5alpha-stigmastane-3beta,6alpha,8,15alpha,16beta-pentaol|29-(alpha-L-arabinofuranosyloxy)-5alpha-stigmastane-3beta,6alpha,8beta,15alpha,16beta-pentaol

29-(alpha-L-arabinofuranosyloxy)-5alpha-stigmastane-3beta,6alpha,8,15alpha,16beta-pentaol|29-(alpha-L-arabinofuranosyloxy)-5alpha-stigmastane-3beta,6alpha,8beta,15alpha,16beta-pentaol

C34H60O10 (628.418626)


   

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

11-oxoasiatic acid triacetate|2alpha,3beta,23-triacetoxy-11-oxo-urs-12-en-28-oic acid|2alpha,3beta,23-Triacetoxy-11-oxo-urs-12-en-28-saeure|2alpha,3beta,23-triacetoxyurs-11-oxo-12-ene-28-oic acid

C36H52O9 (628.3611142)


   
   

De-O-methyltenuicausine

De-O-methyltenuicausine

C40H44N4O3 (628.3413234)


   
   

(20R,24S)-3-O-(2,3-di-O-methyl-beta-D-xylopyranosyl)-5alpha-cholestane-3beta,4beta,6beta,8,15alpha,24-hexaol|tumidoside B

(20R,24S)-3-O-(2,3-di-O-methyl-beta-D-xylopyranosyl)-5alpha-cholestane-3beta,4beta,6beta,8,15alpha,24-hexaol|tumidoside B

C34H60O10 (628.418626)


   
   

11-(3-methylbutanoyl)ilikonapyrone

11-(3-methylbutanoyl)ilikonapyrone

C37H56O8 (628.3974976000001)


   

(25R)-5beta-furostane-1beta,3beta,11alpha,22alpha,26-pentaol 26-O-beta-D-glucopyranoside|caucasicoside F

(25R)-5beta-furostane-1beta,3beta,11alpha,22alpha,26-pentaol 26-O-beta-D-glucopyranoside|caucasicoside F

C33H56O11 (628.3822426)


   
   
   

irciniasulfonic acid O-methyl (Z)-15-docosenoate

irciniasulfonic acid O-methyl (Z)-15-docosenoate

C35H64O7S (628.4372514)


   

onchitriol I A|Onchitriol IA

onchitriol I A|Onchitriol IA

C36H52O9 (628.3611142)


   
   

Phorbol-12-tiglate-13-laurate

Phorbol-12-tiglate-13-laurate

C37H56O8 (628.3974976000001)


   

Integracin A

Integracin A

C37H56O8 (628.3974976000001)


A benzoate ester obtained by the formal condensation of the hydroxy group of 5-(8-hydroxyundecyl)benzene-1,3-diol with 4,6-dihydroxy benzoic acid which is also substituted by a 8-(acetoxy)undecyl group at position 2. It is isolated from Cytonaema sp. and has anti-HIV-1 activity.

   

5beta-cholestane-3alpha,7alpha,12alpha,23,25-pentol-23-glucuronide

5beta-cholestane-3alpha,7alpha,12alpha,23,25-pentol-23-glucuronide

C33H56O11 (628.3822426)


   
   

(2R,3S,2R,3S)-2,3,2,3-tetrahydroxy-beta,beta-carotene-4,4-dione|2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione|2,3,2,3-Tetrahydroxy-beta,beta-caroten-4,4-dion

(2R,3S,2R,3S)-2,3,2,3-tetrahydroxy-beta,beta-carotene-4,4-dione|2,2,3,3-Tetrahydroxy-beta,beta-carotene-4,4-dione|2,3,2,3-Tetrahydroxy-beta,beta-caroten-4,4-dion

C40H52O6 (628.3763692)


   
   
   
   

Lopinavir

Lopinavir (ABT-378)

C37H48N4O5 (628.3624517999999)


D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065692 - Cytochrome P-450 CYP3A Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C97366 - HIV Protease Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors Same as: D01425 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

RLLNN

Arg-Leu-Leu-Asn-Asn

C26H48N10O8 (628.3656408)


   

KRGLR

Lys Arg Gly Leu Arg

C26H52N12O6 (628.4132572000001)


   

PI(20:0/0:0)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587451999999)


   

PA(13:0/18:3(6Z,9Z,12Z))

1-tridecanoyl-2-(6Z,9Z,12Z-octadecatrienoyl)-glycero-3-phosphate

C34H61O8P (628.4103835999999)


   

PA(13:0/18:3(9Z,12Z,15Z))

1-tridecanoyl-2-(9Z,12Z,15Z-octadecatrienoyl)-glycero-3-phosphate

C34H61O8P (628.4103835999999)


   

PA(14:1(9Z)/17:2(9Z,12Z))

1-(9Z-tetradecenoyl)-2-(9Z,12Z-heptadecadienoyl)-glycero-3-phosphate

C34H61O8P (628.4103835999999)


   

PA(17:2(9Z,12Z)/14:1(9Z))

1-(9Z,12Z-heptadecadienoyl)-2-(9Z-tetradecenoyl)-glycero-3-phosphate

C34H61O8P (628.4103835999999)


   

PA(18:3(6Z,9Z,12Z)/13:0)

1-(6Z,9Z,12Z-octadecatrienoyl)-2-tridecanoyl-glycero-3-phosphate

C34H61O8P (628.4103835999999)


   

PA(18:3(9Z,12Z,15Z)/13:0)

1-(9Z,12Z,15Z-octadecatrienoyl)-2-tridecanoyl-glycero-3-phosphate

C34H61O8P (628.4103835999999)


   

2-(9R-(15Z-docosenoyloxy)-3-methyl-2Z-decenoyloxy)-ethanesulfonic acid

2-(9R-(15Z-docosenoyloxy)-3-methyl-2Z-decenoyloxy)-ethanesulfonic acid

C35H64O7S (628.4372514)


   

Bacillamidin E

N-[(2S,3S)-2-[(1S)-1-hydroxy-2-[[(1S)-1-[(3S)-8-hydroxy-1-oxo-3,4-dihydroisochromen-3-yl]-3-methylbutyl]amino]-2-oxoethyl]-5-oxooxolan-3-yl]-13-methyltetradecanamide

C36H56N2O7 (628.4087306000001)


   

LPI 20:0

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587451999999)


   

PA 31:3

1-(9Z,12Z-heptadecadienoyl)-2-(9Z-tetradecenoyl)-glycero-3-phosphate

C34H61O8P (628.4103835999999)


   

Telocinobufagin-3-(14-hydroxymyristate)

3beta,5beta,14beta-trihydroxy-bufa-20,22-dienolide-3beta-yl-14-hydroxy-tetradecanoate

C38H60O7 (628.4338809999999)


   

Astaxanthin-5,6-peroxide

5,6-Peroxy-3,3-dihydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

Astaxanthin-5,8-peroxide

5,8-Peroxy-3,3-dihydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

2,2-Dihydroxyastaxanthin

(2R,3S,2R,3S)-2,3,2,3-Tetrahydroxy-beta,beta-carotene-4,4-dione

C40H52O6 (628.3763692)


   

N,N-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine,4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine

N,N-bis(2,2,6,6-tetramethylpiperidin-4-yl)hexane-1,6-diamine,4-(4,6-dichloro-1,3,5-triazin-2-yl)morpholine

C31H58Cl2N8O (628.4110398)


   

12-hydroxyoctadecanoic acid,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid,oxiran-2-ylmethyl 2-methylprop-2-enoate

12-hydroxyoctadecanoic acid,methyl 2-methylprop-2-enoate,2-methylprop-2-enoic acid,oxiran-2-ylmethyl 2-methylprop-2-enoate

C34H60O10 (628.418626)


   

7-amino-6-[(2-aminoacetyl)amino]-2-[[4-carboxy-4-[2-(dodecanoylamino)propanoylamino]butanoyl]amino]-7-oxoheptanoic acid

7-amino-6-[(2-aminoacetyl)amino]-2-[[4-carboxy-4-[2-(dodecanoylamino)propanoylamino]butanoyl]amino]-7-oxoheptanoic acid

C29H52N6O9 (628.3795582)


   
   

Cholylglycyltyrosine

Cholylglycyltyrosine

C35H52N2O8 (628.3723472)


D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

   

cyclo[DL-Arg-DL-Val-DL-Leu-DL-Leu-DL-Phe]

cyclo[DL-Arg-DL-Val-DL-Leu-DL-Leu-DL-Phe]

C32H52N8O5 (628.4060462)


   

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(10:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C33H57O9P (628.3740002)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(10:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C33H57O9P (628.3740002)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

PA(10:0/20:3(5Z,11Z,14Z)-O(8,9))

C33H57O9P (628.3740002)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

PA(20:3(5Z,11Z,14Z)-O(8,9)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

PA(10:0/20:3(8Z,11Z,14Z)-O(5,6))

C33H57O9P (628.3740002)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

PA(20:3(8Z,11Z,14Z)-O(5,6)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(10:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C33H57O9P (628.3740002)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(10:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(10:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(10:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(10:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C33H57O9P (628.3740002)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/10:0)

C33H57O9P (628.3740002)


   

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(10:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C33H57O9P (628.3740002)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/10:0)

C33H57O9P (628.3740002)


   
   

N-[[(3S,9R,10R)-16-[[anilino(oxo)methyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylcarbamic acid 2-methoxyethyl ester

N-[[(3S,9R,10R)-16-[[anilino(oxo)methyl]amino]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylcarbamic acid 2-methoxyethyl ester

C33H48N4O8 (628.3471968)


   

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3624517999999)


   

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(4-morpholinyl)propanamide

C37H48N4O5 (628.3624517999999)


   
   
   

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] icosanoate

C29H57O12P (628.3587451999999)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

C29H57O12P (628.3587451999999)


   
   
   
   
   
   
   

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

[1-propanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

C34H60O10 (628.418626)


   

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-nonanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C34H60O10 (628.418626)


   

[1-hexanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

[1-hexanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C34H60O10 (628.418626)


   

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-heptanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C34H60O10 (628.418626)


   

[1-butanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

[1-butanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C34H60O10 (628.418626)


   

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

[1-pentanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C34H60O10 (628.418626)


   

[1-octanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-octanoyloxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C34H60O10 (628.418626)


   

(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (10Z,13Z,16Z)-docosa-10,13,16-trienoate

(1-nonanoyloxy-3-phosphonooxypropan-2-yl) (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C34H61O8P (628.4103835999999)


   

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (11Z,14Z,17Z)-icosa-11,14,17-trienoate

(1-phosphonooxy-3-undecanoyloxypropan-2-yl) (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C34H61O8P (628.4103835999999)


   

[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

[1-phosphonooxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C34H61O8P (628.4103835999999)


   

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C34H61O8P (628.4103835999999)


   

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

(1-phosphonooxy-3-tridecanoyloxypropan-2-yl) (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C34H61O8P (628.4103835999999)


   

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

[1-phosphonooxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C34H61O8P (628.4103835999999)


   

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

[1-[(Z)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C34H61O8P (628.4103835999999)


   

[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-hydroxypropan-2-yl] (7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-hydroxypropan-2-yl] (7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoate

C41H56O5 (628.4127526)


   

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C34H61O8P (628.4103835999999)


   

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-3-phosphonooxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (9E,12E)-heptadeca-9,12-dienoate

C34H61O8P (628.4103835999999)


   

[1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[(E)-pentadec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C34H61O8P (628.4103835999999)


   

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

[(2R)-1-phosphonooxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (9E,12E)-heptadeca-9,12-dienoate

C34H61O8P (628.4103835999999)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C34H61O8P (628.4103835999999)


   

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

C34H61O8P (628.4103835999999)


   

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

[(2R)-1-phosphonooxy-3-undecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

C34H61O8P (628.4103835999999)


   

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

[(2R)-3-phosphonooxy-2-undecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

C34H61O8P (628.4103835999999)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C34H61O8P (628.4103835999999)


   

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

[(2R)-3-phosphonooxy-2-tridecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C34H61O8P (628.4103835999999)


   

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (9E,11E,13E)-hexadeca-9,11,13-trienoate

(1-pentadecanoyloxy-3-phosphonooxypropan-2-yl) (9E,11E,13E)-hexadeca-9,11,13-trienoate

C34H61O8P (628.4103835999999)


   

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

[(2R)-1-phosphonooxy-3-tridecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C34H61O8P (628.4103835999999)


   

2-[[3-heptanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-heptanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

2-[hydroxy-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-pentanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

2-[hydroxy-[3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]-2-octanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]-2-octanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

2-[[3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

2-[[2-butanoyloxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-butanoyloxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-nonanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

2-[[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-propanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C33H59NO8P+ (628.3978084)


   

2-[[2-hexanoyloxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-hexanoyloxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3E)-3-ethylidene-2-(2-hydroxyethyl)-2,4-dihydro-1H-indolo[2,3-a]quinolizin-7-yl]propanoate

methyl (2S)-2-[(2R,3E,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-[(2R,3E)-3-ethylidene-2-(2-hydroxyethyl)-2,4-dihydro-1H-indolo[2,3-a]quinolizin-7-yl]propanoate

C40H44N4O3 (628.3413234)


   

2-[hydroxy-[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-octoxypropoxy]phosphoryl]oxyethyl-trimethylazanium

2-[hydroxy-[2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-octoxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

2-[[3-decoxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[3-decoxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

2-[[2-acetyloxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-acetyloxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

2-[[2-decanoyloxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

2-[[2-decanoyloxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C34H63NO7P+ (628.4341918)


   

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

1-eicosanoyl-glycero-3-phospho-(1-myo-inositol)

C29H57O12P (628.3587451999999)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

3-{[4-(methylamino)phenyl]methyl}-6,9,12,15-tetrakis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

3-{[4-(methylamino)phenyl]methyl}-6,9,12,15-tetrakis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

C34H56N6O5 (628.4311966)


   

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

(2r,3r,4s,5s,6e,8r)-8-{6-[(2s,3s)-3-(acetyloxy)pentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-5-hydroxy-4,6-dimethylnon-6-en-3-yl acetate

C36H52O9 (628.3611142)


   

methyl (4as,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (4as,6as,6br,8ar,9r,10r,11s,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

(2s,3r,4s,5r,6s)-6-{[(2s,3r,4s,5s,6r)-2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

C32H52O12 (628.3458592)


   

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

(1'r,2s,3r,4's,5s,6s,8'r,10'e,13'r,14'e,16'z,21'r,24's)-6-[(2e)-but-2-en-2-yl]-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611142)


   

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

6-(but-2-en-2-yl)-3,24'-dihydroxy-18',21'-dimethoxy-5,11',13',22'-tetramethyl-3',7',19'-trioxaspiro[oxane-2,6'-tetracyclo[15.6.1.1⁴,⁸.0²⁰,²⁴]pentacosane]-10',14',16',22'-tetraen-2'-one

C36H52O9 (628.3611142)


   

methyl (4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

(3e,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3e,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7r)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

blattellastanoside b

NA

C35H61ClO7 (628.4105586000001)


{"Ingredient_id": "HBIN018647","Ingredient_name": "blattellastanoside b","Alias": "NA","Ingredient_formula": "C35H61ClO7","Ingredient_Smile": "NA","Ingredient_weight": "629.31","OB_score": "NA","CAS_id": "151397-98-7","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "6172","PubChem_id": "NA","DrugBank_id": "NA"}

   

(4s)-11-(3,5-dihydroxyphenyl)undecan-4-yl 2-[(8s)-8-(acetyloxy)undecyl]-4,6-dihydroxybenzoate

(4s)-11-(3,5-dihydroxyphenyl)undecan-4-yl 2-[(8s)-8-(acetyloxy)undecyl]-4,6-dihydroxybenzoate

C37H56O8 (628.3974976000001)


   

(1r,2r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,5s)-5-(2-{[(2r,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}ethyl)-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,7-pentol

(1r,2r,3r,3as,3bs,5s,5as,7s,9as,9br,11ar)-1-[(2r,5s)-5-(2-{[(2r,3r,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}ethyl)-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,7-pentol

C34H60O10 (628.418626)


   

6-({2-[(3,7-dimethylocta-1,6-dien-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxy)-4,5-dihydroxy-2-methyloxan-3-yl 6-hydroxy-2,6-dimethylocta-2,7-dienoate

6-({2-[(3,7-dimethylocta-1,6-dien-3-yl)oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl}oxy)-4,5-dihydroxy-2-methyloxan-3-yl 6-hydroxy-2,6-dimethylocta-2,7-dienoate

C32H52O12 (628.3458592)


   

2-{[(2z,9r)-9-[(15z)-docos-15-enoyloxy]-3-methyldec-2-enoyl]oxy}ethanesulfonic acid

2-{[(2z,9r)-9-[(15z)-docos-15-enoyloxy]-3-methyldec-2-enoyl]oxy}ethanesulfonic acid

C35H64O7S (628.4372514)


   

(3e,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7s)-6,10-dimethyl-7-{[(2r,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3e,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7s)-6,10-dimethyl-7-{[(2r,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

(2s,6r)-6-[(1r,3as,5ar,7s,9as,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-11-oxo-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,7s,9as,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-11-oxo-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H56O8 (628.3974976000001)


   

(3z,3as,5ar,7r,9ar,9bs)-3-(6,10-dimethyl-7-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene)-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-(6,10-dimethyl-7-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene)-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

7-[(5-hydroxy-3,4-dimethoxyoxan-2-yl)oxy]-1-(5-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,6-tetrol

7-[(5-hydroxy-3,4-dimethoxyoxan-2-yl)oxy]-1-(5-hydroxy-6-methylheptan-2-yl)-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,6-tetrol

C34H60O10 (628.418626)


   

(3r,6s,9r,12s,15r)-3-{[4-(dimethylamino)phenyl]methyl}-9-isopropyl-6,12,15-tris(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

(3r,6s,9r,12s,15r)-3-{[4-(dimethylamino)phenyl]methyl}-9-isopropyl-6,12,15-tris(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

C34H56N6O5 (628.4311966)


   

methyl (1s,2r,4as,6as,6br,8ar,9s,10r,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

methyl (1s,2r,4as,6as,6br,8ar,9s,10r,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

3-{6,10-dimethyl-7-[(3,4,5-trihydroxyoxan-2-yl)oxy]undeca-3,5,9-trien-2-ylidene}-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

3-{6,10-dimethyl-7-[(3,4,5-trihydroxyoxan-2-yl)oxy]undeca-3,5,9-trien-2-ylidene}-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6r)-6-hydroxytetradeca-2,4-dienoate

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6r)-6-hydroxytetradeca-2,4-dienoate

C36H52O9 (628.3611142)


   

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7s)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7s)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

methyl (1s,2r,4as,6as,6br,8ar,9r,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

methyl (1s,2r,4as,6as,6br,8ar,9r,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

methyl 10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl 10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

methyl (1s,2r,4as,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

methyl (1s,2r,4as,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

2-[(2s,3r,5s,6s)-6-[(3s,4s,6r)-6-[(2s,2'r,3'r,4s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxypropyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-3,5-dimethyloxan-2-yl]ethaneperoxoic acid

2-[(2s,3r,5s,6s)-6-[(3s,4s,6r)-6-[(2s,2'r,3'r,4s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxypropyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-3,5-dimethyloxan-2-yl]ethaneperoxoic acid

C34H60O10 (628.418626)


   

3-{[4-(dimethylamino)phenyl]methyl}-9-isopropyl-6,12,15-tris(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

3-{[4-(dimethylamino)phenyl]methyl}-9-isopropyl-6,12,15-tris(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

C34H56N6O5 (628.4311966)


   

(3s)-5-{[(1r,3as,5ar,7s,9as,11s,11ar)-1-[(2r)-1-[(2s)-3,4-dimethyl-5-oxo-2h-furan-2-yl]propan-2-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

(3s)-5-{[(1r,3as,5ar,7s,9as,11s,11ar)-1-[(2r)-1-[(2s)-3,4-dimethyl-5-oxo-2h-furan-2-yl]propan-2-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

C37H56O8 (628.3974976000001)


   

3-[18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

3-[18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

C40H52O6 (628.3763692)


   

(3s)-5-{[(1r,3as,5ar,7r,9as,11s,11ar)-1-[(2r)-1-[(2s)-3,4-dimethyl-5-oxo-2h-furan-2-yl]propan-2-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

(3s)-5-{[(1r,3as,5ar,7r,9as,11s,11ar)-1-[(2r)-1-[(2s)-3,4-dimethyl-5-oxo-2h-furan-2-yl]propan-2-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

C37H56O8 (628.3974976000001)


   

3-[(9e,11e,13e,15e,17e)-18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

3-[(9e,11e,13e,15e,17e)-18-(4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

C40H52O6 (628.3763692)


   

(2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

(2r)-2-[(1r,3ar,5ar,7r,9as,11ar)-7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methyl-5-methylideneheptanoic acid

C38H60O7 (628.4338809999999)


   

1,5,12,16,24,28-hexahydroxy-1,6,12,17,24,29-hexaazacyclopentatriaconta-5,16,28-triene-2,13,25-trione

1,5,12,16,24,28-hexahydroxy-1,6,12,17,24,29-hexaazacyclopentatriaconta-5,16,28-triene-2,13,25-trione

C29H52N6O9 (628.3795582)


   

2-(6-{6-[5'-ethyl-2'-hydroxy-5'-(1-hydroxyethyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl}-2-hydroxy-3,5-dimethyloxan-2-yl)propanoic acid

2-(6-{6-[5'-ethyl-2'-hydroxy-5'-(1-hydroxyethyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl}-2-hydroxy-3,5-dimethyloxan-2-yl)propanoic acid

C34H60O10 (628.418626)


   

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7s)-6,10-dimethyl-7-{[(2r,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e,7s)-6,10-dimethyl-7-{[(2r,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

(5r,6s)-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4s,5r)-4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

(5r,6s)-3-[(1e,3e,5e,7e,9e,11e,13e,15e,17e)-18-[(4s,5r)-4,5-dihydroxy-2,6,6-trimethyl-3-oxocyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-5,6-dihydroxy-2,4,4-trimethylcyclohex-2-en-1-one

C40H52O6 (628.3763692)


   

(3z,3as,5ar,7r,9ar,9bs)-3-(6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene)-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-(6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene)-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

1-[5-(2-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}ethyl)-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,7-pentol

1-[5-(2-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}ethyl)-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-2,3,3b,5,7-pentol

C34H60O10 (628.418626)


   

(3s,6s,9s,12s,20as)-12-benzyl-1,4,7,10,13-pentahydroxy-6-[(1r)-1-hydroxyethyl]-3,9-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

(3s,6s,9s,12s,20as)-12-benzyl-1,4,7,10,13-pentahydroxy-6-[(1r)-1-hydroxyethyl]-3,9-bis(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C32H48N6O7 (628.3584298000001)


   

(3z,5e,7r,8s,9s,11e,13e,15s,16r)-16-[(2s,3r,4s,6e,10e,12e)-3,9-dihydroxy-4,8-dimethyl-5-oxotetradeca-6,10,12-trien-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

(3z,5e,7r,8s,9s,11e,13e,15s,16r)-16-[(2s,3r,4s,6e,10e,12e)-3,9-dihydroxy-4,8-dimethyl-5-oxotetradeca-6,10,12-trien-2-yl]-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

C37H56O8 (628.3974976000001)


   

(2s)-2-[(2r,3r,5s,6s)-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxyethyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2-hydroxy-3,5-dimethyloxan-2-yl]propanoic acid

(2s)-2-[(2r,3r,5s,6s)-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxyethyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2-hydroxy-3,5-dimethyloxan-2-yl]propanoic acid

C34H60O10 (628.418626)


   

(1r,3s,3as,3bs,5r,5as,6r,7s,9as,9br,11ar)-7-{[(2s,3r,4s,5r)-5-hydroxy-3,4-dimethoxyoxan-2-yl]oxy}-1-[(2r,5s)-5-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,6-tetrol

(1r,3s,3as,3bs,5r,5as,6r,7s,9as,9br,11ar)-7-{[(2s,3r,4s,5r)-5-hydroxy-3,4-dimethoxyoxan-2-yl]oxy}-1-[(2r,5s)-5-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,5,6-tetrol

C34H60O10 (628.418626)


   

16-(3,9-dihydroxy-4,8-dimethyl-5-oxotetradeca-6,10,12-trien-2-yl)-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

16-(3,9-dihydroxy-4,8-dimethyl-5-oxotetradeca-6,10,12-trien-2-yl)-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyl-1-oxacyclohexadeca-3,5,11,13-tetraen-2-one

C37H56O8 (628.3974976000001)


   

methyl (1s,2r,10r,17s,19s,20r,22s,23s,27r,39s)-17,22-diethyl-21-oxa-3,13,24,34-tetraazadodecacyclo[20.15.1.1¹⁰,¹³.0¹,²⁴.0²,²⁷.0³,²⁰.0⁴,⁹.0¹⁰,²⁰.0¹⁹,²³.0²⁷,³⁵.0²⁸,³³.0¹⁷,³⁹]nonatriaconta-4,6,8,15,28,30,32,35-octaene-36-carboxylate

methyl (1s,2r,10r,17s,19s,20r,22s,23s,27r,39s)-17,22-diethyl-21-oxa-3,13,24,34-tetraazadodecacyclo[20.15.1.1¹⁰,¹³.0¹,²⁴.0²,²⁷.0³,²⁰.0⁴,⁹.0¹⁰,²⁰.0¹⁹,²³.0²⁷,³⁵.0²⁸,³³.0¹⁷,³⁹]nonatriaconta-4,6,8,15,28,30,32,35-octaene-36-carboxylate

C40H44N4O3 (628.3413234)


   

(2r,3r,4r,5r,6e,8s)-5-(acetyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2s,3s)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethylnon-6-en-3-yl acetate

(2r,3r,4r,5r,6e,8s)-5-(acetyloxy)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2s,3s)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethylnon-6-en-3-yl acetate

C36H52O9 (628.3611142)


   

6-[(2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

6-[(2-{[(3r)-3,7-dimethylocta-1,6-dien-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl)oxy]-4,5-dihydroxy-2-methyloxan-3-yl (2e,6r)-6-hydroxy-2,6-dimethylocta-2,7-dienoate

C32H52O12 (628.3458592)


   

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e)-6,10-dimethyl-7-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e)-6,10-dimethyl-7-{[(2s,3r,4r,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

(3z,3as,5ar,7r,9ar,9bs)-3-[(3e,5e)-6,10-dimethyl-7-{[(2s,3s,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}undeca-3,5,9-trien-2-ylidene]-3a,6,6,9a-tetramethyl-2-oxo-octahydrocyclopenta[a]naphthalen-7-yl acetate

C37H56O8 (628.3974976000001)


   

5-({1-[1-(3,4-dimethyl-5-oxo-2h-furan-2-yl)propan-2-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-3-hydroxy-3-methyl-5-oxopentanoic acid

5-({1-[1-(3,4-dimethyl-5-oxo-2h-furan-2-yl)propan-2-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-3-hydroxy-3-methyl-5-oxopentanoic acid

C37H56O8 (628.3974976000001)


   

[(1r,2s,6r,10s,11r,13s,15r)-1,6-dihydroxy-4,12,12,15-tetramethyl-13-(octanoyloxy)-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-8-yl]methyl decanoate

[(1r,2s,6r,10s,11r,13s,15r)-1,6-dihydroxy-4,12,12,15-tetramethyl-13-(octanoyloxy)-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-8-yl]methyl decanoate

C38H60O7 (628.4338809999999)


   

methyl 10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

methyl 10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

methyl (1s,12s,14r,15z,18s)-15-ethylidene-12-[(11s,12z,17s)-12-ethylidene-10-formyl-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6,9-tetraen-4-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

methyl (1s,12s,14r,15z,18s)-15-ethylidene-12-[(11s,12z,17s)-12-ethylidene-10-formyl-8,14-diazapentacyclo[9.5.2.0¹,⁹.0²,⁷.0¹⁴,¹⁷]octadeca-2,4,6,9-tetraen-4-yl]-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C40H44N4O3 (628.3413234)


   

[(2s,3r,5s,6s)-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxypropyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2-hydroxy-3,5-dimethyloxan-2-yl]acetic acid

[(2s,3r,5s,6s)-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-[(1s)-1-hydroxypropyl]-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2-hydroxy-3,5-dimethyloxan-2-yl]acetic acid

C34H60O10 (628.418626)


   

(3r,6s,9r,12s,15r)-3-{[4-(methylamino)phenyl]methyl}-6,9,12,15-tetrakis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

(3r,6s,9r,12s,15r)-3-{[4-(methylamino)phenyl]methyl}-6,9,12,15-tetrakis(2-methylpropyl)-1,4,7,10,13-pentaazacyclopentadeca-1,4,7,10,13-pentaene-2,5,8,11,14-pentol

C34H56N6O5 (628.4311966)


   

2-{7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-6-methyl-5-methylideneheptanoic acid

2-{7-[(3-hydroxy-5-methoxy-3-methyl-5-oxopentanoyl)oxy]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl}-6-methyl-5-methylideneheptanoic acid

C38H60O7 (628.4338809999999)


   

(2s)-2-[(2r,3r,5s,6s)-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-(1-hydroxyethyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2-hydroxy-3,5-dimethyloxan-2-yl]propanoic acid

(2s)-2-[(2r,3r,5s,6s)-6-[(2s,3s,4s,6r)-6-[(2s,2'r,3'r,4s,5s,5'r)-5'-ethyl-2'-hydroxy-5'-(1-hydroxyethyl)-2,3',4-trimethyl-[2,2'-bioxolan]-5-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-2-hydroxy-3,5-dimethyloxan-2-yl]propanoic acid

C34H60O10 (628.418626)


   

methyl (4as,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

methyl (4as,6as,6br,8ar,9r,10r,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6s)-6-hydroxytetradeca-2,4-dienoate

(1r,2s,6r,10s,11r,12s,13s,15r)-12-[(acetyloxy)methyl]-1,6-dihydroxy-8-(hydroxymethyl)-4,12,15-trimethyl-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-13-yl (2e,4e,6s)-6-hydroxytetradeca-2,4-dienoate

C36H52O9 (628.3611142)


   

[1,6-dihydroxy-4,12,12,15-tetramethyl-13-(octanoyloxy)-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-8-yl]methyl decanoate

[1,6-dihydroxy-4,12,12,15-tetramethyl-13-(octanoyloxy)-5-oxotetracyclo[8.5.0.0²,⁶.0¹¹,¹³]pentadeca-3,8-dien-8-yl]methyl decanoate

C38H60O7 (628.4338809999999)


   

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-11-oxo-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

(2s,6r)-6-[(1r,3as,5ar,7r,9as,11ar)-7-{[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}-3a,6,6,9a,11a-pentamethyl-11-oxo-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h-cyclopenta[a]phenanthren-1-yl]-2-methyl-3-methylideneheptanoic acid

C37H56O8 (628.3974976000001)


   

methyl (1s,2r,4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

methyl (1s,2r,4as,6as,6br,8ar,9s,10s,11r,12ar,12br,14bs)-10,11-bis(acetyloxy)-9-[(acetyloxy)methyl]-1,2,6a,6b,9,12a-hexamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a-carboxylate

C37H56O8 (628.3974976000001)


   

11-(3,5-dihydroxyphenyl)undecan-4-yl 2-[8-(acetyloxy)undecyl]-4,6-dihydroxybenzoate

11-(3,5-dihydroxyphenyl)undecan-4-yl 2-[8-(acetyloxy)undecyl]-4,6-dihydroxybenzoate

C37H56O8 (628.3974976000001)